Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials.
Corticosteroids
Fatigue
Meta-analysis
Prostate cancer
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
27
10
2018
accepted:
26
11
2018
pubmed:
7
12
2018
medline:
18
12
2019
entrez:
7
12
2018
Statut:
ppublish
Résumé
Cancer-related fatigue (CRF) is a complex condition that is reported in > 50% of cancer patients. In men with castration-resistant prostate cancer (CRPC), CRF was reported in 12-21% of patients. Approved systemic therapy against CRPC is commonly administered in combination with androgen-deprivation treatment (ADT) and, in some cases, with daily, low-dose corticosteroids. Importantly, the use of low-dose corticosteroids is associated with multiple negative effects, including reduced muscle mass. On these grounds, we hypothesized that the chronic use of corticosteroids may increase the incidence of fatigue in patients with prostate cancer. We reviewed all randomized trials published during the last 15 years conducted in patients with prostate cancer receiving systemic treatment and we performed a sub-group analysis to gather insights regarding the potential differences in the incidence of fatigue in patients receiving vs. not receiving daily corticosteroids as part of their systemic anti-neoplastic regimen. Overall, 22,734 men enrolled in prospective randomized phase II and III trials were evaluable for fatigue. Estimated pooled incidence of grade 1-2 fatigue was 30.89% (95% CI = 25.34-36.74), while estimated pooled incidence of grade 3-4 fatigue was reported in 3.90% (95% CI = 2.91-5.02). Sub-group analysis showed that grade 3-4 fatigue was approximately double in patients who received daily corticosteroids as part of their anti-neoplastic treatment (5.58; 95% CI = 4.33-6.98) vs. those who did not (2.67%; 95% CI = 1.53-4.11). Our findings highlight the need for ad hoc-designed prospective clinical trials to investigate whether the benefits associated with low-dose, daily corticosteroids outweigh the risks associated with corticosteroid-related adverse events such as fatigue.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer-related fatigue (CRF) is a complex condition that is reported in > 50% of cancer patients. In men with castration-resistant prostate cancer (CRPC), CRF was reported in 12-21% of patients. Approved systemic therapy against CRPC is commonly administered in combination with androgen-deprivation treatment (ADT) and, in some cases, with daily, low-dose corticosteroids. Importantly, the use of low-dose corticosteroids is associated with multiple negative effects, including reduced muscle mass. On these grounds, we hypothesized that the chronic use of corticosteroids may increase the incidence of fatigue in patients with prostate cancer.
METHODS
METHODS
We reviewed all randomized trials published during the last 15 years conducted in patients with prostate cancer receiving systemic treatment and we performed a sub-group analysis to gather insights regarding the potential differences in the incidence of fatigue in patients receiving vs. not receiving daily corticosteroids as part of their systemic anti-neoplastic regimen.
RESULTS
RESULTS
Overall, 22,734 men enrolled in prospective randomized phase II and III trials were evaluable for fatigue. Estimated pooled incidence of grade 1-2 fatigue was 30.89% (95% CI = 25.34-36.74), while estimated pooled incidence of grade 3-4 fatigue was reported in 3.90% (95% CI = 2.91-5.02). Sub-group analysis showed that grade 3-4 fatigue was approximately double in patients who received daily corticosteroids as part of their anti-neoplastic treatment (5.58; 95% CI = 4.33-6.98) vs. those who did not (2.67%; 95% CI = 1.53-4.11).
CONCLUSION
CONCLUSIONS
Our findings highlight the need for ad hoc-designed prospective clinical trials to investigate whether the benefits associated with low-dose, daily corticosteroids outweigh the risks associated with corticosteroid-related adverse events such as fatigue.
Identifiants
pubmed: 30519742
doi: 10.1007/s00345-018-2579-x
pii: 10.1007/s00345-018-2579-x
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
1049-1059Références
Eur J Cancer Care (Engl). 2003 Mar;12(1):20-7
pubmed: 12641553
Invest New Drugs. 2011 Dec;29(6):1432-40
pubmed: 20336348
J Clin Oncol. 2015 Mar 1;33(7):723-31
pubmed: 25624429
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
J Clin Oncol. 2008 Dec 20;26(36):5936-42
pubmed: 19029421
J Clin Oncol. 2016 Sep 1;34(25):3005-13
pubmed: 27400947
J Clin Oncol. 2017 Oct 1;35(28):3181-3188
pubmed: 28632486
Eur Urol. 2009 May;55(5):1112-23
pubmed: 19042080
J Clin Oncol. 1989 May;7(5):590-7
pubmed: 2709088
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Invest New Drugs. 2014 Aug;32(4):746-52
pubmed: 24671507
J Clin Oncol. 2014 Jan 10;32(2):76-82
pubmed: 24323035
J Natl Compr Canc Netw. 2015 Aug;13(8):1012-39
pubmed: 26285247
J Clin Oncol. 2015 May 10;33(14):1601-8
pubmed: 25847934
BJU Int. 2011 Jan;107(2):234-9
pubmed: 20590545
Stroke. 2009 Oct;40(10):e586-7; author reply e590
pubmed: 19745174
Lancet Oncol. 2015 Apr;16(4):417-25
pubmed: 25743937
Clin Cancer Res. 2011 Jul 1;17(13):4558-67
pubmed: 21558406
Future Oncol. 2014 Jun;10(8):1353-60
pubmed: 25052746
Rev Prat. 2011 Apr;61(4):538-41
pubmed: 21548240
J Urol. 2014 Mar;191(3):657
pubmed: 24522034
Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):268-76
pubmed: 24837889
Prostate Cancer Prostatic Dis. 2012 Mar;15(1):87-92
pubmed: 22006050
Clin Genitourin Cancer. 2016 Feb;14(1):5-11
pubmed: 26390963
J Cancer. 2017 Aug 22;8(14):2663-2668
pubmed: 28928853
J Clin Oncol. 2005 Mar 1;23(7):1439-46
pubmed: 15735119
J Clin Oncol. 2008 Nov 10;26(32):5261-8
pubmed: 18794543
Expert Rev Mol Diagn. 2016 Oct;16(10):1113-1120
pubmed: 27665838
Ann Oncol. 2007 Jun;18(6):1064-70
pubmed: 17434899
J Clin Oncol. 2017 Oct 1;35(28):3198-3206
pubmed: 28809610
Medicine (Baltimore). 2016 Jan;95(2):e2299
pubmed: 26765406
Clin Cancer Res. 2005 May 1;11(9):3353-62
pubmed: 15867235
Clin Cancer Res. 2008 Apr 15;14(8):2437-43
pubmed: 18413835
J Endocrinol Invest. 2005;28(11 Suppl International):21-7
pubmed: 16625841
Lancet Oncol. 2013 Dec;14(13):1307-16
pubmed: 24211163
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Cancer. 2006 Aug 1;107(3):530-5
pubmed: 16804927
BJU Int. 2008 Nov;102(9):1080-5
pubmed: 18485028
Eur Urol. 2012 Apr;61(4):850
pubmed: 22373884
J Clin Oncol. 2017 Jan;35(1):40-47
pubmed: 28034081
Clin Genitourin Cancer. 2012 Mar;10(1):6-14
pubmed: 22340631
Eur Urol. 2015 May;67(5):825-36
pubmed: 25097095
Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61
pubmed: 21365219
Clin Cancer Res. 2014 Apr 1;20(7):1925-34
pubmed: 24536060
Br J Cancer. 2011 Feb 15;104(4):613-9
pubmed: 21285986
Prostate. 2016 Dec;76(16):1519-1527
pubmed: 27457964
Lancet Oncol. 2017 Nov;18(11):1532-1542
pubmed: 29033099
Clin Genitourin Cancer. 2018 Apr;16(2):e277-e287
pubmed: 29352714
J Urol. 2009 Mar;181(3):1104-13; discussion 1113
pubmed: 19167733
J Clin Oncol. 1996 Jun;14(6):1756-64
pubmed: 8656243
Endocr Relat Cancer. 2014 Aug;21(4):T87-T103
pubmed: 24859991
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Handb Exp Pharmacol. 2016;233:73-93
pubmed: 25917083
Lancet Oncol. 2016 Feb;17(2):153-163
pubmed: 26774508
J Clin Oncol. 2017 Oct 1;35(28):3189-3197
pubmed: 28753384
Lancet Oncol. 2017 Apr;18(4):473-485
pubmed: 28283282
BJU Int. 2006 Sep;98(3):580-5
pubmed: 16925757
J Clin Oncol. 2004 Jul 1;22(13):2532-9
pubmed: 15226321
J Urol. 2005 Mar;173(3):790-6
pubmed: 15711271
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Invest New Drugs. 2013 Aug;31(4):1044-50
pubmed: 23435622
Clin Cancer Res. 2010 Nov 1;16(21):5269-76
pubmed: 20978144
Lancet Oncol. 2015 Mar;16(3):338-48
pubmed: 25701170